

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

CD20

RRID:AB_1727449

Type: Antibody

Proper Citation

BD Biosciences Cat# 560734, RRID:AB_1727449

Antibody Information

URL: http://antibodyregistry.org/AB_1727449

Proper Citation: BD Biosciences Cat# 560734, RRID:AB_1727449

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD20

Description: This monoclonal targets CD20

Target Organism: human

Antibody ID: AB_1727449

Vendor: BD Biosciences

Catalog Number: 560734

Record Creation Time: 20250819T213540+0000

Record Last Update: 20250819T232757+0000

Ratings and Alerts

No rating or validation information has been found for CD20.

No alerts have been found for CD20.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Picard M, et al. (2025) Persistent myeloid cell reprogramming despite miltefosine treatment in leishmania-infected macaques. *iScience*, 28(12), 113900.

Feng Y, et al. (2025) Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine. *Cell host & microbe*, 33(5), 705.

Lopes de Assis F, et al. (2023) Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine. *Cell reports*, 42(7), 112780.

Ortiz AM, et al. (2023) Experimental bacterial dysbiosis with consequent immune alterations increase intrarectal SIV acquisition susceptibility. *Cell reports*, 42(1), 112020.

Matassoli F, et al. (2023) High frequency of HIV precursor-target-specific B cells in sub-Saharan populations. *Cell reports*, 42(12), 113450.

Wimmers F, et al. (2023) Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth. *Cell*, 186(21), 4632.

Matveev VA, et al. (2023) Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. *iScience*, 26(10), 107915.

Garcia-Valtanen P, et al. (2022) SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. *Cell reports. Medicine*, 3(6), 100651.

Buckner CM, et al. (2022) Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. *Cell*, 185(23), 4333.

Balachandran H, et al. (2022) Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. *Cell reports*, 38(6), 110345.

Abayasingam A, et al. (2021) Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. *Cell reports. Medicine*, 2(4), 100228.

Rijal P, et al. (2019) Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. *Cell reports*, 27(1), 172.

Hagan T, et al. (2019) Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. *Cell*, 178(6), 1313.